Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALVARO M MURCIA

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1104822261
CMS profile
231014
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$606.94

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $594.49 31
Education $12.45 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALVARO M MURCIA

NPI 1104822261 · CMS profile ID 231014

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104822261?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALVARO M MURCIA, NPI 1104822261, CMS profile ID 231014. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104822261?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ALVARO M MURCIA, NPI 1104822261, CMS profile ID 231014. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104822261?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ALVARO M MURCIA, NPI 1104822261, CMS profile ID 231014, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1104822261?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $606.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $15.0411/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067713 CMS
Regeneron Healthcare Solutions, Inc. $18.0711/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445151 CMS
Janssen Pharmaceuticals, Inc $16.3311/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067709 CMS
AstraZeneca Pharmaceuticals LP $22.9510/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685783351 CMS
Regeneron Healthcare Solutions, Inc. $20.3310/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445149 CMS
Janssen Pharmaceuticals, Inc $17.4809/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067705 CMS
PFIZER INC. $13.9109/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672889137 CMS
Amarin Pharma Inc. $18.2008/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699185259 CMS
AstraZeneca Pharmaceuticals LP $23.5407/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685065653 CMS
Janssen Pharmaceuticals, Inc $23.3007/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067701 CMS
PFIZER INC. $13.9107/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672646783 CMS
Janssen Pharmaceuticals, Inc $17.2006/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067699 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.5405/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700463627 CMS
E.R. Squibb & Sons, L.L.C. $19.3905/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651371935 CMS
Regeneron Healthcare Solutions, Inc. $12.4505/13/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445147 CMS
Regeneron Healthcare Solutions, Inc. $20.2105/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445145 CMS
Janssen Pharmaceuticals, Inc $18.3305/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067695 CMS
SANOFI-AVENTIS U.S. LLC $24.4204/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694301349 CMS
AstraZeneca Pharmaceuticals LP $16.9804/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685637409 CMS
PFIZER INC. $13.9104/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672044197 CMS
Regeneron Healthcare Solutions, Inc. $27.1104/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445143 CMS
Janssen Pharmaceuticals, Inc $16.6404/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067691 CMS
Novartis Pharmaceuticals Corporation $18.0703/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659762372 CMS
Amarin Pharma Inc. $18.5803/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699104805 CMS
Amgen Inc. $20.0003/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663206187 CMS
Regeneron Healthcare Solutions, Inc. $28.5302/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445141 CMS
PFIZER INC. $13.9102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672013409 CMS
AstraZeneca Pharmaceuticals LP $18.2302/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685210629 CMS
ARBOR PHARMACEUTICALS, INC. $14.4201/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697365623 CMS
SANOFI-AVENTIS U.S. LLC $14.2801/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694272427 CMS
Janssen Pharmaceuticals, Inc $17.4801/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067685 CMS
Regeneron Healthcare Solutions, Inc. $30.2001/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445139 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $606.94 32
PY2020 $366.85 18
PY2021 $465.58 22
PY2023 $20.75 1
PY2024 $169.48 4
PY2025 $127.06 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $406,482.03 21
PY2024 Principal investigator $1,460,913.18 46
PY2023 Principal investigator $709,095.23 72
PY2022 Principal investigator $649,259.15 51
PY2021 Principal investigator $536,745.12 32
PY2020 Principal investigator $88,190.48 30
PY2019 Principal investigator $148,033.20 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $70,383.10 12/31/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130971942
Principal investigator 1 PFIZER INC. $56,902.50 12/24/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130971853
Principal investigator 1 PFIZER INC. $18,711.00 12/20/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130973082
Principal investigator 1 PFIZER INC. $24,017.51 12/05/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130971936
Principal investigator 1 PFIZER INC. $31,436.77 11/26/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130984812
Principal investigator 1 PFIZER INC. $5,853.60 11/26/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130984818
Principal investigator 1 PFIZER INC. $10,975.50 11/08/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130984824
Principal investigator 1 PFIZER INC. $31,853.25 11/05/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130985035
Principal investigator 1 PFIZER INC. $20,578.47 10/24/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130997376
Principal investigator 1 PFIZER INC. $43,875.00 10/05/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130996822
Principal investigator 1 PFIZER INC. $365.85 10/05/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130997383
Principal investigator 1 PFIZER INC. $85,346.80 09/25/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131022671
Principal investigator 1 PFIZER INC. $13,231.50 09/11/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131022479
Principal investigator 1 PFIZER INC. $52,750.00 09/11/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131022677
Principal investigator 1 PFIZER INC. $5,346.00 08/27/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131032532
Principal investigator 1 PFIZER INC. $5,184.00 07/29/2024 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130916931
Principal investigator 1 PFIZER INC. $1,036.80 07/29/2024 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130918921
Principal investigator 1 PFIZER INC. $7,425.00 07/11/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131045563
Principal investigator 1 PFIZER INC. $2,984.51 06/25/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131069577
Principal investigator 1 PFIZER INC. $169,873.00 06/21/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131069891
Principal investigator 1 PFIZER INC. $26,484.30 06/05/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131066902
Principal investigator 1 PFIZER INC. $5,062.50 06/04/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131066517
Principal investigator 1 PFIZER INC. $218.70 05/29/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131080289
Principal investigator 1 PFIZER INC. $20,428.54 05/29/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131080977
Principal investigator 1 PFIZER INC. $121,212.75 05/24/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131080301
Principal investigator 1 PFIZER INC. $131,646.60 05/24/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131080971
Principal investigator 1 PFIZER INC. $1,297.01 05/03/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131080295
Principal investigator 1 Novartis Pharmaceuticals Corporation $69,686.82 04/29/2024 Non-covered Recipient Entity
DBC RESEARCH USA
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease No dispute reported 06/30/2026 1089692737
Principal investigator 1 PFIZER INC. $2,594.02 04/26/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131087037
Principal investigator 1 PFIZER INC. $45,119.15 04/05/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131086864
Principal investigator 1 PFIZER INC. $15,579.00 04/05/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131087031
Principal investigator 1 PFIZER INC. $293.50 04/04/2024 Non-covered Recipient Entity
DBC Research USA
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131022123
Principal investigator 1 PFIZER INC. $19,117.80 03/28/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104773
Principal investigator 1 PFIZER INC. $534.30 03/28/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104836
Principal investigator 1 PFIZER INC. $4,673.70 03/27/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104767
Principal investigator 1 PFIZER INC. $2,073.60 03/08/2024 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1130917922
Principal investigator 1 PFIZER INC. $45,844.80 03/08/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104807
Principal investigator 1 PFIZER INC. $52,250.40 02/27/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104796
Principal investigator 1 PFIZER INC. $20,798.10 02/14/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104779
Principal investigator 1 PFIZER INC. $15,650.00 02/13/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131104801
Principal investigator 1 PFIZER INC. $1,336.50 01/26/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131108324
Principal investigator 1 Novartis Pharmaceuticals Corporation $196,958.27 01/23/2024 Non-covered Recipient Entity
DBC RESEARCH USA
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1089692669
Principal investigator 1 PFIZER INC. $3,192.75 01/20/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS No dispute reported 06/30/2026 1131107272
Principal investigator 1 PFIZER INC. $469.60 01/16/2024 Non-covered Recipient Entity
DBC Research USA
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131022129
Principal investigator 1 PFIZER INC. $30.08 01/16/2024 Non-covered Recipient Entity
DBC Research USA
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131022682
Principal investigator 1 PFIZER INC. $230.23 01/09/2024 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131106737